Results 251 to 260 of about 2,453,999 (317)

Therapeutic use of oral gastrografin in treating acute adhesive small bowel obstruction. [PDF]

Bioinformation
Soni S, Prakash S, Rai S, Philips S.
europepmc   +1 more source

Finding novel vulnerabilities of hypomorphic BRCA1 alleles

Molecular Oncology, EarlyView.
Synthetic lethality screens performed to identify novel vulnerabilities often model complete gene loss, thereby overlooking patient‐derived hypomorphic mutations. In this study, we have performed genome‐wide CRISPR screens on BRCA1 hypomorphic mutations, showing BRCA1I26A behaves like wild‐type, while BRCA1R1699Q mimics deficiency. Furthermore, we have
Anne Schreuder, Klaas de Lint, Hồ Mỹ Phúc Võ, Mariana M. Góis, Rosalie A. Kampen, Marta San Martin Alonso, Ilse Nootenboom, Veronica Garzero, Tiemen J. Wendel, Rob M. F. Wolthuis, Sylvie M. Noordermeer   +10 more
wiley   +1 more source

The Therapeutic Use of Dental Mesenchymal Stem Cells in Human Clinical Trials. [PDF]

J Dent Res
Ivanovski S, Han P, Peters OA, Sanz M, Bartold PM.   +4 more
europepmc   +1 more source

Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer

Molecular Oncology, EarlyView.
Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi, Stavros Makrodimitris, Sandra van Wilpe, Iris te Paske, Vanja de Weerd, Corine M. Beaufort, Hans M. Westgeest, Jens Voortman, Maureen J. B. Aarts, Maud Rijnders, Astrid A. M. van der Veldt, Ronald de Wit, Niven Mehra, Saskia M. Wilting, Debbie G. J. Robbrecht   +14 more
wiley   +1 more source

MITF maintains genome stability in nonmelanocyte lineages

Molecular Oncology, EarlyView.
MITF is essential for melanocyte survival and acts as an oncogene in 10%–20% of melanomas. We show that MITF depletion causes genome instability in nonmelanocytic cells, leading to LATS2‐mediated P53 activation, cell cycle arrest, and apoptosis. This study highlights the role of MITF as a genome maintenance factor beyond the melanocyte lineage. Created
Drifa H. Gudmundsdottir, Adrián López García de Lomana, Thejus B. Venkatesh, Kritika Kirty, Snaevar Sigurdsson, Linda Vidarsdottir, Ramile Dilshat, Erla Sveinbjornsdottir, Snaedis Ragnarsdottir, Daniel H Magnusson, Maria R. Bustos, Eirikur Steingrimsson, Thorkell Gudjonsson, Stefan Sigurdsson   +13 more
wiley   +1 more source

The therapeutic use of clonal neural stem cells in experimental Parkinson´s disease. [PDF]

Stem Cell Res Ther
Nelke A, García-López S, Caso JR, Pereira MP.   +3 more
europepmc   +1 more source

Tissue engineering for therapeutic use 3 proceedings of the Third International Symposium on Tissue Engineering for Therapeutic Use, Tokyo, Japan, 4-5 September 1998

, 1999
International Symposium of Tissue Engineering for Therapeutic Use 1998 Tokio, Ikada, Yoshito   +1 more
core  

Therapeutic use of music in neurological disorders: A concise narrative review. [PDF]

Heliyon
Ramaswamy M, Philip JL, Priya V, Priyadarshini S, Ramasamy M, Jeevitha GC, Mathkor DM, Haque S, Dabaghzadeh F, Bhattacharya P, Ahmad F.   +10 more
europepmc   +1 more source

Tissue engineering for therapeutic use 6 proceedings of the Sixth International Symposium on Tissue Engineering for Therapeutic Use, Suita, Osaka, Japan 25-26 October 2001

, 2002
International Symposium on Tissue Engineering for Therapeutic Use 2001 Suita; Ōsaka, Ikada, Yoshito   +1 more
core  

Therapeutic Use of γ-Hydroxybutyrate: History and Clinical Utility of Oxybates and Considerations of Once- and Twice-Nightly Dosing in Narcolepsy. [PDF]

CNS Drugs
Roth T.
europepmc   +1 more source